Viking Therapeutics (VKTX) Stock Trades At A Premium To Book Value
Viking Therapeutics (VKTX) stock trades at a price-to-book (P/B) ratio of 5.6x, significantly above the biotech sector average of 1.7x, suggesting it is overvalued based on this metric. Despite a strong multi-year share price run and recent progress with its obesity drug candidate VK2735, the current valuation implies a rich price tag. However, some bullish analyst narratives suggest the stock could be undervalued by as much as 79% if long-term outcomes for VK2735 align with optimistic forecasts.
Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing
Viking Therapeutics is planning a potential 2029 launch for its obesity drug candidate VK2735 and is currently exploring less frequent injection schedules and a daily oral tablet for weight maintenance. CEO Brian Lian stated that the company is open to partnerships but is also building capabilities for an independent launch. The firm has four Phase 3 trials underway, with initial data expected in late 2027 and oral Phase 3 results anticipated in 2028.
Viking Therapeutics Erases Takeover-Driven Gain as VK2735 Obesity Data Fails to Impress
Viking Therapeutics shares fell on Monday, erasing a takeover-driven gain from Friday, after new obesity data for its VK2735 drug failed to present significant new findings. While the data from the Phase 2 VENTURE trial showed promising BMI improvements and cardiometabolic health benefits, it primarily added detail to previously reported mean weight loss figures rather than a new headline. Investors are now focused on the Phase 3 VANQUISH program, with topline data expected in 2027.
Viking Therapeutics Stock Dips Despite Positive VK2735 Data: What’s Going On?
Shares of Viking Therapeutics Inc (NASDAQ: VKTX) dropped about 5% despite the company presenting positive exploratory analysis data from its Phase 2 VENTURE trial for VK2735. The analysis showed that 74% of participants receiving weekly VK2735 injections improved by at least one BMI category, alongside improvements in cardiometabolic health markers. The stock's decline is attributed to traders potentially viewing the analysis as adding detail rather than new information, following previous reports of significant weight loss, and VKTX's current trading below key moving averages.
Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus
Viking Therapeutics (VKTX) is drawing attention after presenting new VK2735 obesity data, leading to short-term stock momentum despite a negative one-year return. Simply Wall St's bullish analyst narrative suggests the stock is 77% undervalued with a fair value of $125, driven by optimistic projections for VK2735 and the broader obesity pipeline. However, the SWS DCF model presents a contrasting view, flagging the stock as overvalued with a fair value of just $3.16 per share, highlighting a significant valuation debate.
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Viking Therapeutics announced new clinical data from its VK2735 obesity program were highlighted at ObesityWeek® 2026. An exploratory analysis of the Phase 2 VENTURE trial showed that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, alongside improvements in multiple cardiometabolic markers. The company also presented baseline characteristics from the ongoing Phase 3 VANQUISH-2 study, which is evaluating subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes.
Viking Therapeutics reports lower BMI category in 74% on VK2735
Viking Therapeutics announced that 74% of participants treated with VK2735 achieved a lower BMI category, compared to 15% on placebo, after 13 weeks in an exploratory obesity analysis from its Phase 2 VENTURE trial. These new findings include cardiometabolic markers, complementing previously released weight-loss and tolerability data. The company's pivotal injection studies are slated for completion in 2027, with Phase 3 trials like VANQUISH-1 and VANQUISH-2 currently underway.
Viking Therapeutics gains amid report of renewed takeover interest
Viking Therapeutics (VKTX) stock rose by 4.1% following renewed speculation of a potential takeover, though the suitor's identity remains unknown. Past speculation has linked Eli Lilly, Pfizer, and Novo Nordisk to Viking. The company is scheduled to present at two upcoming biopharma conferences.
Viking Therapeutics (VKTX) Stock Could Be Pricey Following VK2735 Obesity Data Plans
Viking Therapeutics' stock has seen a significant price increase over the past five years, raising questions about its current valuation relative to its book value, especially with upcoming VK2735 obesity program data. Despite a P/B ratio of 6.2x, which is above the biotech sector average, analysts hold optimistic views, with one narrative suggesting the stock is 77% undervalued based on potential future growth and differentiated labeling for VK2735. The article cautions investors to consider factors beyond valuation models, such as management incentives, before making investment decisions.
Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
Viking Therapeutics (VKTX) has seen significant share returns, raising questions about whether its current price of US$28.44 is justified by its balance sheet, especially following ObesityWeek 2026 presentations on its obesity drug candidate, VK2735. The stock's price-to-book (P/B) ratio of 6.2x suggests it's overvalued compared to the broader biotech sector, though closer to its peer group. A bullish analyst narrative suggests the company could be 77% undervalued based on optimistic forecasts for VK2735's potential.
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
Viking Therapeutics (VKTX) has experienced a bullish reversal, targeting $43.55, following a post-earnings rally from $23.82 and the triggering of an inverse head-and-shoulders pattern above $28.00. The stock has a history of strong momentum, with a prior 1,100% rally, and current support was found at a significant prior resistance area. Further strength is anticipated with a reclaim of moving averages and a breakout above the consolidation range, potentially signaling the end of a longer-term correction.
Obesity Trial Data Might Change The Case For Investing In Viking Therapeutics Stock
Viking Therapeutics recently reported a net loss of US$183.19 million in Q3 2026 and plans to present new VK2735 obesity data at upcoming conferences. The company's investment narrative is heavily reliant on the success of its VK2735 obesity drug development, with analysts projecting significant revenue and profit by 2029 despite current losses. Upcoming data presentations are critical for influencing investor confidence and evaluating the competitive landscape in the obesity treatment market.
Viking Therapeutics (VKTX) Moved, What Is Drawing Attention Now?
Viking Therapeutics (VKTX) reported a net loss of US$183.19 million in Q3 2026, widening its losses for the first nine months of the year, against a backdrop of declining share prices. Despite a 3-year total shareholder return of over 170%, the stock's recent performance is down, leading to mixed signals regarding its valuation. The company's future hinges on the success of its Phase III SUNRISE trials for oral VK2735 in obesity treatment.
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics will present two posters at ObesityWeek® 2026, highlighting data from its VK2735 program. The presentations will cover baseline characteristics from the Phase 3 VANQUISH-2 trial of subcutaneous VK2735 and the impact of VK2735 on obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for metabolic disorders, including obesity, in both subcutaneous and oral formulations.
Viking Therapeutics, Inc. (VKTX) Seasonal returns chart
This article provides a seasonal returns chart for Viking Therapeutics, Inc. (VKTX), showing the average monthly price return from 2016 to 2026. The stock's current real-time price on NasdaqCM is also displayed, along with after-hours trading information. It highlights the stock's performance and historical seasonality data.
A passive holder reports 9.54 million Viking Therapeutics (VKTX) shares in an amended disclosure.
FMR LLC has filed an amended disclosure (SCHEDULE 13G/A) reporting a 7.7% passive stake in Viking Therapeutics, Inc. (VKTX). As of September 30, 2026, FMR LLC beneficially owned 9,539,067 shares, with sole voting power over 9,503,286 shares and sole dispositive power over 9,539,067 shares. Abigail P. Johnson also reported sole dispositive power over the same number of shares.
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics announced its management will participate in five investor conferences in November and December 2026, including Stifel, UBS, Jefferies, and Piper Sandler. These engagements will feature fireside chats and one-on-one meetings, providing shareholders with direct access to management. Webcasts of some fireside chats will be available on the company's website.
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. announced its participation in multiple investor conferences during November and December 2026, including the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. Management will engage in fireside chats and investor meetings to discuss their clinical-stage biopharmaceutical programs focused on metabolic and endocrine disorders. The company is advancing therapies for obesity and metabolic diseases, with lead programs like VK2735, a dual GLP-1 and GIP receptor agonist, in Phase 3 clinical studies.
Two talks by Viking Therapeutics will be streamed online
Viking Therapeutics (NASDAQ: VKTX) will participate in five investor conferences in November and December 2026, with management attending investor meetings. Two of these fireside chats, at the Jefferies Global Healthcare Conference and the Piper Sandler 38th Annual Healthcare Conference, will be available via live webcast and subsequent replays on the company's website. The company will also participate in conferences hosted by Stifel, Truist, and UBS.
Viking Therapeutics, Inc. (VKTX) options chain
This article provides an options chain for Viking Therapeutics, Inc. (VKTX), detailing its current stock price and pre-market activity. As of the data provided, there were no call or put options available in the money for VKTX. The information is delayed by 15 minutes.
Viking Therapeutics Stock Jumps: What's Going On?
Viking Therapeutics (VKTX) shares surged after the company reported third-quarter results that included a wider-than-expected loss but also positive study data for its obesity drug, VK2735, and a strong cash balance of $960 million. The positive news regarding VK2735's weight maintenance efficacy and the initiation of Phase 3 trials for its oral version appear to be outweighing the financial miss. The company also announced plans for two Phase 3 trials for the tablet version of VK2735, aiming to be the first oral drug to target both GLP-1 and GIP pathways.
Viking Therapeutics, Inc. (VKTX) Seasonal returns chart
This article from Yahoo Finance provides a seasonal returns chart for Viking Therapeutics, Inc. (VKTX), detailing its average monthly price return from 2016 to 2026. It also includes current stock information, recent earnings call details, and related market data.
Viking Therapeutics Stock Jumps: What's Going On?
Viking Therapeutics (NASDAQ: VKTX) shares surged after the company reported wider-than-expected Q3 losses but also positive study data for its obesity drug, VK2735, and a strong cash balance of $960 million. The positive news about VK2735's weight maintenance efficacy and the advancement of its oral version into Phase 3 trials appears to be outweighing the financial miss. The company is funding multiple late-stage trials and preparing for a potential drug launch.
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail
Viking Therapeutics (VKTX) shares dropped after reporting a wider-than-expected Q3 loss and CEO Brian Lian's announcement of a two-and-a-half-year timeline for its obesity drug (VK2735) launch. The company, which is developing both injectable and oral versions of VK2735, is undertaking four Phase 3 trials. While retail sentiment on Stocktwits was mixed, with some criticizing the CEO's timeline, others defended the company's progress.
Viking Therapeutics falls on third quarter loss miss
Viking Therapeutics Inc (NASDAQ:VKTX) reported a third-quarter loss of $1.55 per share, missing analyst estimates due to increased spending on its obesity drug development programs. The company's net loss widened to $183.2 million, driven by higher research and development expenses for ongoing clinical studies and manufacturing of drug candidates. Despite the financial miss, Viking continued to advance its SUNRISE Phase 3 program for oral VK2735 and VANQUISH Phase 3 trials for subcutaneous VK2735, with positive results from maintenance dosing studies.
Viking Therapeutics falls on third quarter loss miss
Viking Therapeutics (NASDAQ:VKTX) reported a larger-than-expected third-quarter loss due to increased spending on its obesity drug development programs. The company posted a loss of $1.55 per share, missing analyst estimates, and saw its shares fall 2.4% in after-hours trading. Despite the loss, Viking continued to advance its Phase 3 programs for oral and subcutaneous VK2735 and initiated Part 2 of a maintenance study after positive weight loss retention results.
Earnings Flash (VKTX) Viking Therapeutics, Inc. Reports Q3 Revenue $0K
Viking Therapeutics, Inc. (VKTX) announced its Q3 revenue was $0K. This suggests the company is in a developmental phase with no product revenue yet.
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics announced its financial results for Q3 2026, highlighting significant advancements in its obesity pipeline, including the initiation of Phase 3 trials for both subcutaneous and oral formulations of VK2735. The company also reported positive results from its VK2735 maintenance dosing study and a strong quarter-end cash position of $960 million. These developments are intended to support the continued advancement of its drug candidates and prepare for potential commercial launch.
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics announced its Q3 2026 financial results, reporting a net loss of $183.2 million, and provided a corporate update highlighting the advancement of its obesity franchise. Key developments include the initiation of Phase 3 trials for both subcutaneous and oral VK2735, positive results from a VK2735 maintenance dosing study, and the nearing completion of a Phase 1 study for the amylin agonist VK3019. The company also reported a strong cash position of $960 million to support its pipeline and potential commercial launch of VK2735.
How Oral Obesity Trials At Viking Therapeutics (VKTX) Has Changed Its Investment Story
Viking Therapeutics has begun its SUNRISE Phase 3 program for oral VK2735 in obesity and type 2 diabetes, a move that significantly escalates development costs and operational complexity, adding to its existing injectable trials. This shift requires the company, currently at zero revenue and operating at a loss, to manage a larger cash burn towards a potential commercial obesity franchise. Future earnings reports and trial timelines will be crucial in determining the viability of its ambitious 2029 revenue and earnings targets.
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
Viking Therapeutics (VKTX) is preparing to report its Q3 2026 earnings, with analysts expecting a loss per share as the company has no marketed drugs. Investor focus will likely be on the progress of its obesity pipeline, particularly the lead candidate VK2735 in both subcutaneous and oral formulations, with phase III trial updates anticipated in 2027. Despite a 31% year-to-date stock decline, the article suggests the recent dip could be a buying opportunity due to potential positive catalysts from VK2735's development and the company's strong financial position.
Why Viking Therapeutics’ Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics is set to report its third-quarter results on October 28, with its stock having fallen over 41% in the past month. The call will focus heavily on the newly launched Phase 3 program for its oral obesity drug, VK2735, and the company's financial outlook amidst rising R&D costs. Investors are looking for clarity on the trial's specifics and how maintenance dosing data will position VK2735 against competitors.
How Viking Therapeutics Inc. (VKTX) Affects Rotational Strategy Timing
This article by Stock Traders Daily analyzes Viking Therapeutics Inc. (VKTX) stock, providing proprietary signals and institutional trading strategies based on AI models. It highlights a neutral near-term sentiment and potential mid-term weakness, with elevated downside risk, offering specific entry zones, targets, and stop losses for position, momentum breakout, and risk hedging strategies across different time horizons.
Viking Therapeutics, Inc. Estimates – NASDAQ:VKTX
The article provides a financial overview of Viking Therapeutics, Inc. (NASDAQ: VKTX) on TradingView. It details where users can explore reported financial data and analyst estimates, including income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Viking Therapeutics stock hits 52-week low at 24.94 USD By Investing.com
Viking Therapeutics Inc. stock recently hit a 52-week low of $24.94, trading slightly above this floor at $24.88. The biotechnology company, with a market capitalization of $2.93 billion, has seen a significant 27.08% decline over the past year. Despite the downturn, the company holds more cash than debt and is anticipating earnings results in five days, with analysts offering mixed reactions to recent developments like public offerings and obesity treatment trial data.
Viking Therapeutics stock hits 52-week low at 24.94 USD
Viking Therapeutics Inc. (VKTX) stock has reached a new 52-week low of $24.94, trading just above this floor, reflecting a significant -27.08% decline over the past year. Despite the downturn, the biotechnology company holds more cash than debt. Investors are closely monitoring its performance as earnings results are due in five days, amidst mixed analyst reactions following recent public offering proposals and varied opinions on its obesity treatment pipeline.
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
This article compares Novo Nordisk (NVO) and Viking Therapeutics (VKTX), two companies operating in the burgeoning obesity-treatment market, to determine which offers greater investment potential. While Novo Nordisk holds a leading position with established GLP-1 drugs like Ozempic and Wegovy, it faces intense competition from Eli Lilly. Viking Therapeutics, a clinical-stage biotech, presents a higher-risk, higher-reward opportunity with its investigational dual GIP and GLP-1 receptor agonist, VK2735, showing promising clinical results for weight reduction and maintenance.
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Viking Therapeutics (NASDAQ: VKTX) announced it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide general corporate updates. A replay of the call will be available until November 4, 2026, and a webcast archive will be accessible on Viking's website for 30 days.
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Viking Therapeutics, Inc. announced it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide general corporate updates. A telephone replay and webcast archive will be available for those unable to attend the live call.
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Viking Therapeutics, Inc. announced it will release its financial results for the third quarter of 2026 after market close on Wednesday, October 28, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide general corporate updates. A telephone replay and webcast archive will be available for those unable to attend the live call.
Viking Therapeutics (VKTX) Stock Still Looks Overvalued On Its 357% Five Year Run
Viking Therapeutics (VKTX) has experienced a significant 357% stock gain over five years, fueled by its obesity drug pipeline, raising questions about its current valuation. The stock trades at a considerable premium to the biotech industry's book value, particularly due to high investor confidence in its oral VK2735 Phase 3 trials. While a community narrative suggests it's 79% undervalued, Simply Wall St's analysis flags it as overvalued relative to its sector, implying high expectations are already embedded in the price.
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
This article highlights four biotechnology companies—BridgeBio Pharma (BBIO), Intellia Therapeutics (NTLA), Biogen (BIIB), and Viking Therapeutics (VKTX)—that have promising late-stage drug pipelines. These companies are nearing significant milestones such as FDA decisions, pivotal study readouts, and new drug applications. The article details their key drug candidates, their current clinical trial phases, and the potential market impact of their approvals and launches.
Weekly Recap: VKTX $502M cash & $548M raise and VK2735 oral GLP‑1/GIP
Viking Therapeutics, Inc. (VKTX) has significantly strengthened its financial position with $502 million in cash as of June 30 and an additional $548 million raised in September. This capital infusion is earmarked to advance its obesity and metabolic pipeline, with a particular focus on VK2735, an oral dual GLP-1/GIP agonist. The company plans to position VK2735 as either an induction or maintenance therapy, contingent on successful Phase 3 trial results.
Viking Therapeutics (VKTX) As SUNRISE Phase 3 Starts Is The Stock Fully Priced
Viking Therapeutics (VKTX) has initiated its SUNRISE Phase 3 program for oral VK2735, following successful Phase 2 trials and fully enrolled injectable trials. Despite this progress, the stock has seen a significant pullback, with its share price down over 30% in 90 days and 28.9% year-to-date, suggesting that traders are reassessing trial risks and timing. Valuation models show the stock trading at an expensive price-to-book ratio of 7.2x, significantly higher than its peers and the broader biotech sector, and a DCF model suggests it is overvalued at $25.17 compared to an estimated future cash flow value of $8.
Historical Data for Viking Therapeutics Inc (Derivatives) in USD
This page provides historical data for Viking Therapeutics Inc (Derivatives) in USD on CryptoRank.io. Users can view and download daily, weekly, monthly, or quarterly data including open, high, low, average, close prices, change, volume, and market capitalization. The platform also offers various other crypto market analytics and tools.
H.C. Wainwright targets Viking Therapeutics stock at USD 102.00: Viking starts Phase 3 trials
H.C. Wainwright has reiterated a Buy rating and a $102.00 price target for Viking Therapeutics after the company began two Phase 3 studies for its oral VK2735 drug. These trials, targeting 560 adults each, will run for 68 weeks. The valuation remains dependent on future clinical development and regulatory execution, with the next earnings report due on October 28, 2026.
Viking Therapeutics Stock In Focus As Earnings Near And Obesity Trial Advances
Viking Therapeutics is heavily investing in its VK2735 obesity asset, with the oral version now in Phase 3 SUNRISE trials and expanded maintenance dosing studies, building on promising Phase 2 data. Despite the significant clinical progress and potential, the company currently operates without revenue, reporting substantial losses, which puts pressure on the successful execution of its trials to transition from a clinical-stage to a commercial-stage entity. Analyst forecasts project revenue and profitability by 2029, but current valuations highlight the high sensitivity to changes in the VK2735 program's expected margins, timing, or market uptake.
Viking Therapeutics Slides as Financing Overhang and Competitive Concerns Weigh on Sentiment
Viking Therapeutics (VKTX) stock fell 7.4% due to ongoing investor concerns about dilution from its late-September stock and convertible note financing, as well as competitive pressures in the crowded obesity-drug market. This decline occurred despite the company recently advancing its oral VK2735 program into Phase 3. Insider selling and mixed institutional investor activity also highlight the cautious sentiment surrounding the company.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) experienced an 8.26% decline, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. The company's shares have also decreased by 6.78% over the last month, contrasting with gains in the Medical sector and S&P 500. Investors are anticipating Viking Therapeutics' upcoming earnings report, with forecasts predicting a decrease in EPS, though recent analyst estimate revisions have been slightly positive, leading to a Zacks Rank of #2 (Buy).
VKTX Initiated Coverage by UBS -- Rating Set to Buy with Price T
UBS has initiated coverage on Viking Therapeutics (VKTX) with a Buy rating and a price target of $94.00, suggesting significant upside from its current trading price of $27.37. Despite this positive outlook, the company has a low GF Score™ of 34/100, indicating challenges in financial health and profitability, particularly due to its clinical-stage status and lack of product revenue. Investors are presented with a complex picture, balancing analyst confidence with notable insider selling and the company's financial risks.